ICER publishes evidence report on treatments for obesity management

31 August 2022 - Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide ...

Read more →

ICER publishes evidence report on treatments for amyotrophic lateral sclerosis

4 August 2022 - Given current data, AMX0035 is comparable or better to standard of care; AMX0035 would achieve common thresholds ...

Read more →

ICER publishes final evidence report and policy recommendations on beti-cel gene therapy for beta thalassaemia

19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net ...

Read more →

ICER releases draft evidence report on treatments for obesity management

13 July 2022 - Registration now open for 26 July “Early Insights” webinar. ...

Read more →

ICER launches initiative to evaluate and advance health technology assessment methods that support health equity

11 July 2022 - Funding from Commonwealth Fund supports a broad based initiative exploring potential changes in all health technology assessment ...

Read more →

ICER releases draft evidence report on treatments for amyotrophic lateral sclerosis

14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public ...

Read more →

ICER publishes evidence report on gene therapy for beta thalassaemia

2 June 2022 - Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassaemia. ...

Read more →

ICER to assess treatment for vasomotor symptoms associated with menopause

1 June 2022 - Report will be subject of Midwest CEPAC meeting in December 2022; draft scoping document open to ...

Read more →

ICER publishes final evidence report and policy recommendations on outpatient treatments for COVID-19

10 May 2022 - Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit ...

Read more →

ICER to assess gene therapies for haemophilia A and B

5 May 2022 - Report will be subject of CTAF meeting in November 2022; draft scoping document open to public ...

Read more →

ICER’s favourable assessment of Bluebird Bio’s gene therapy Zynteglo may have important pricing and reimbursement implications

5 May 2022 - ICER evaluated the clinical and cost-effectiveness - as well as budgetary impact - of one of two ...

Read more →

ICER to assess treatments for multiple sclerosis

21 April 2022 - Report will be subject of New England CEPAC meeting in January 2023; draft scoping document open ...

Read more →

ICER publishes 2022 research protocol for assessing unsupported price increases on prescription drugs

14 April 2022 - Final assessment to be published on 6 December 2022. ...

Read more →

ICER releases draft evidence report on gene therapy for beta thalassaemia

13 April 2022 - Public comment period now open until 10 May 2022; requests to make oral comment during public ...

Read more →

ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage

7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...

Read more →